Efficacy and safety of intensive versus conventional glucose targets in people with type 2 diabetes: a systematic review and meta-analysis

References

• Association AD. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37(Suppl 1):S81–90.
   PubMedGoogle Scholar
• Fong DS, Aiello LP, Ferris FL 3rd, et al. Diabetic retinopathy. Diabetes Care. 2004;27(10):2540–2553.
   PubMed Web of Science ®Google Scholar
• Association CDSCM. [A nationwide retrospective analysis on chronic diabetic complications and related macrovascular diseases of in-patients with diabetes during 1991-2000]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2002;24(5):447–451.
   PubMedGoogle Scholar
• Heald A, Stedman M, Robinson A, et al. Mortality rate associated with diabetes: outcomes from a general practice level analysis in England using the royal college of general practitioners (rcgp) database indicate stability over a 15 year period. Diabetes Ther. 2022;13(3):505–516.
   PubMed Web of Science ®Google Scholar
• Global, regional, and national age-sex-specific mortality for. 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1736–1788.
   PubMed Web of Science ®Google Scholar
• Raghavan S, Vassy JL, Ho YL, et al. Diabetes mellitus–related all‐cause and cardiovascular mortality in a National cohort of adults. J Am Heart Assoc. 2019;8(4):e011295.
   PubMed Web of Science ®Google Scholar
• Moran GM, Bakhai C, Song SH, et al. Type 2 diabetes: summary of updated NICE guidance. Bmj. 2022;377:o775.
   PubMedGoogle Scholar
• Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care. 1995;18(2):258–268.
   PubMed Web of Science ®Google Scholar
• Pirart J. [Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973 (3rd and last part) (author’s transl)]. Diabetes Metab. 1977;3(4):245–256.
   PubMed Web of Science ®Google Scholar
• Groeneveld Y, Petri H, Hermans J, et al. Relationship between blood glucose level and mortality in type 2 diabetes mellitus: a systematic review. Diabet Med. 1999;16(1):2–13.
   PubMed Web of Science ®Google Scholar
• Wei M, Gaskill SP, Haffner SM, et al. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The san antonio heart study. Diabetes Care. 1998;21(7):1167–1172.
   PubMed Web of Science ®Google Scholar
• Adler AI, Boyko EJ, Ahroni JH, et al. Risk factors for diabetic peripheral sensory neuropathy. results of the Seattle prospective diabetic foot study. Diabetes Care. 1997;20(7):1162–1167.
   PubMed Web of Science ®Google Scholar
• Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). Bmj. 1998;316(7134):823–828.
   PubMed Web of Science ®Google Scholar
• Lehto S, Rönnemaa T, Pyörälä K, et al. Predictors of stroke in middle-aged patients with non-insulin-dependent diabetes. Stroke. 1996;27(1):63–68.
   PubMed Web of Science ®Google Scholar
• Standl E, Balletshofer B, Dahl B, et al. Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich general practitioner Project. Diabetologia. 1996;39(12):1540–1545.
   PubMed Web of Science ®Google Scholar
• Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141(6):421–431.
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Pogue J, Mann JF, et al. The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia. 2005;48(9):1749–1755.
   PubMed Web of Science ®Google Scholar
• Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Bmj. 2000;321(7258):405–412.
   PubMed Web of Science ®Google Scholar
• Azad N, Agrawal L, Emanuele NV, et al. Association of blood glucose control and pancreatic reserve with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT). Diabetologia. 2014;57(6):1124–1131.
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–2559.
   PubMed Web of Science ®Google Scholar
• Zoungas S, de Galan BE, Ninomiya T, et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial. Diabetes Care. 2009;32(11):2068–2074.
   PubMed Web of Science ®Google Scholar
• Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A consensus report by the American diabetes association (ADA) and the European Association for the study of diabetes (EASD). Diabetes Care. 2022;45(11):2753–2786.
   PubMed Web of Science ®Google Scholar
• Qaseem A, Wilt TJ, Kansagara D, et al. Hemoglobin A1c targets for glycemic control with pharmacologic therapy for nonpregnant adults with Type 2 diabetes mellitus: a guidance statement update from the American college of physicians. Ann Intern Med. 2018;168(8):569–576.
   PubMed Web of Science ®Google Scholar
• Nathan DM, Genuth S, Lachin J, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–986.
   PubMed Web of Science ®Google Scholar
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type. 2 diabetes (UKPDS 33) . UK prospective diabetes study (UKPDS) Group. Lancet 1998;352(9131):837–853.
   PubMed Web of Science ®Google Scholar
• Guo LX, Pan Q, Wang XX, et al. Effect of short term intensive multitherapy on carotid intima-media thickness in patients with newly diagnosed type 2 diabetes mellitus. Chin Med J (Engl). 2008;121(8):687–690.
   PubMed Web of Science ®Google Scholar
• Hemmingsen B, Lund SS, Gluud C, et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011;(6):Cd008143.
   PubMed Web of Science ®Google Scholar
• Hemmingsen B, Lund SS, Gluud C, et al. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ. 2011;343(Nov 24):d6898.
   PubMedGoogle Scholar
• Zhang C-Y, Sun A-J, Zhang S-N, et al. Effects of intensive glucose control on incidence of cardiovascular events in patients with type 2 diabetes: a meta-analysis. Ann Med. 2010;42(4):305–315.
   PubMed Web of Science ®Google Scholar
• Sardar P, Udell JA, Chatterjee S, et al. Effect of intensive versus standard blood glucose control in patients with type 2 diabetes mellitus in different regions of the world: systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2015;5(4):5e001577.
   Google Scholar
• Ueki K, Sasako T, Okazaki Y, et al. Multifactorial intervention has a significant effect on diabetic kidney disease in patients with type 2 diabetes. Kidney Int. 2021;99(1):256–266.
   PubMed Web of Science ®Google Scholar
• Sasso FC, Pafundi PC, Simeon V, et al. Efficacy and durability of multifactorial intervention on mortality and MACEs: a randomized clinical trial in type-2 diabetic kidney disease. Cardiovasc Diabetol. 2021;20(1):1–12.
   PubMed Web of Science ®Google Scholar
• Group AS. Nine-year effects of 3.7 years of intensive glycemic control on cardiovascular outcomes. Diabetes Care. 2016;39(5):701–708.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions. John Wiley & Sons. 2019.
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–269.
   PubMed Web of Science ®Google Scholar
• Abraira C, Colwell J, Nuttall F, et al. Cardiovascular events and correlates in the veterans affairs diabetes feasibility trial. veterans affairs cooperative study on Glycemic Control and Complications in Type II diabetes. Arch Int Med. 1997;157(2):181–188.
   PubMedGoogle Scholar
• Bagg W, Ferri C, Desideri G, et al. The influences of obesity and glycemic control on endothelial activation in patients with type 2 diabetes. J Clin Endocrinol Metab. 2001;86(11):5491–5497.
   PubMed Web of Science ®Google Scholar
• Beulens JW, Patel A, Vingerling JR, et al. Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial. Diabetologia. 2009;52(10):2027–2036.
   PubMed Web of Science ®Google Scholar
• Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–139.
   PubMed Web of Science ®Google Scholar
• Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580–591.
   PubMed Web of Science ®Google Scholar
• Griffin SJ, Borch-Johnsen K, Davies MJ, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet. 2011;378(9786):156–167.
   PubMed Web of Science ®Google Scholar
• Group AtCCRiDS. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–2559.
   PubMed Web of Science ®Google Scholar
• Hage C, Norhammar A, Grip L, et al. Glycaemic control and restenosis after percutaneous coronary interventions in patients with diabetes mellitus: a report from the Insulin Diabetes Angioplasty study. Diab Vasc Dis Res. 2009;6(2):71–79.
   PubMed Web of Science ®Google Scholar
• Jaber LA, Halapy H, Fernet M, et al. Evaluation of a pharmaceutical care model on diabetes management. Ann Pharmacother. 1996;30(3):238–243.
   PubMed Web of Science ®Google Scholar
• Johansen MY, MacDonald CS, Hansen KB, et al. Effect of an Intensive Lifestyle Intervention on glycemic control in patients with Type 2 Diabetes: a randomized clinical trial. Jama. 2017;318(7):637–646.
   PubMed Web of Science ®Google Scholar
• Lapina IV, Filatov DN, Mareev V, et al. Effect of strict glycemic control on clinical state and course of the disease in patients with chronic heart failure and type II diabetes mellitus. Results of the REMBO “rational effective multicomponent therapy in the struggle against diabetes mellitus in patients with congestive heart failure” study]. Kardiologiia 2008;48(9):17–27.
   PubMed Web of Science ®Google Scholar
• Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28(2):103–117.
   PubMed Web of Science ®Google Scholar
• Webb D, Dales J, Zaccardi F, et al. Intensive versus standard multifactorial cardiovascular risk factor control in screen-detected type 2 diabetes: 5-year and longer-term modelled outcomes of the ADDITION-Leicester study. Diabetes Metab Res Rev. 2019;35(3):e3111.
   PubMed Web of Science ®Google Scholar
• Yang JM, Guo XH, Yu X. Long-term intensive glycemic and lipid control ameliorates the carotid intima medial thickness in type 2 diabetes mellitus] Beijing da xue xue bao Yi xue ban. JPeking Univ Health Sci. 2007;39(6):649–652.
   Google Scholar
• Zhang Q, Zhang N, Hu HL, et al. Effect of intensive blood glucose control on quality of life in elderly patients with type 2 diabetes in Anhui Province. Chin Med J (Engl). 2011;124(11):1616–1622.
   PubMed Web of Science ®Google Scholar
• Bonds DE, Kurashige EM, Bergenstal R, et al. Severe hypoglycemia monitoring and risk management procedures in the action to control cardiovascular risk in diabetes (ACCORD) trial. Am J Cardiol. 2007;99(12a):80i–9i.
   PubMed Web of Science ®Google Scholar
• Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010;340(Jan 08):b4909.
   PubMedGoogle Scholar
• Buse JB, Bigger JT, Byington RP, et al. Action to Control cardiovascular risk in diabetes (ACCORD) trial: design and methods. Am J Cardiol. 2007;99(12a):21i–33i.
   PubMed Web of Science ®Google Scholar
• Chew EY, Ambrosius WT, Davis MD, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363(3):233–244.
   PubMed Web of Science ®Google Scholar
• Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575–1585.
   PubMed Web of Science ®Google Scholar
• Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563–1574.
   PubMed Web of Science ®Google Scholar
• Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376(9739):419–430.
   PubMed Web of Science ®Google Scholar
• Persistent Effects of Intensive Glycemic Control on Retinopathy in Type. 2 diabetes in the action to control cardiovascular risk in diabetes (ACCORD) follow-on study. Diabetes Care. 2016;39(7):1089–1100.
   PubMed Web of Science ®Google Scholar
• Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010;363(15):1410–1418.
   PubMed Web of Science ®Google Scholar
• Bagg W, Plank LD, Gamble G, et al. The effects of intensive glycaemic control on body composition in patients with type 2 diabetes. Diabetes Obes Metab. 2001;3(6):410–416.
   PubMed Web of Science ®Google Scholar
• Bagg W, Whalley GA, Gamble G, et al. Effects of improved glycaemic control on endothelial function in patients with type 2 diabetes. Intern Med J. 2001;31(6):322–328.
   PubMed Web of Science ®Google Scholar
• Fatemi O, Yuriditsky E, Tsioufis C, et al. Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). Am J Cardiol. 2014;114(8):1217–1222.
   PubMed Web of Science ®Google Scholar
• Goldman MP, Clark CJ, Craven TE, et al. Effect of intensive glycemic control on risk of lower extremity amputation. J Am Coll Surg. 2018;227(6):596–604.
   PubMed Web of Science ®Google Scholar
• Goldman MP, Corriere MA, Craven T, et al. Evaluation of neuropathy, glycemic control, and revascularization as risk factors for future lower extremity amputation among diabetic patients. Ann Vasc Surg. 2021;73:254–263.
   PubMed Web of Science ®Google Scholar
• Hirakawa Y, Arima H, Zoungas S, et al. Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial. Diabetes Care. 2014;37(8):2359–2365.
   PubMed Web of Science ®Google Scholar
• Yngen M, Norhammar A, Hjemdahl P, et al. Effects of improved metabolic control on platelet reactivity in patients with type 2 diabetes mellitus following coronary angioplasty. Diab Vasc Dis Res. 2006;3(1):52–56.
   PubMedGoogle Scholar
• Kloecker DE, Khunti K, Davies MJ, et al. Microvascular disease and risk of cardiovascular events and death from intensive treatment in Type 2 Diabetes: the ACCORDION Study. Mayo Clin Proc. 2021;96(6):1458–1469.
   PubMed Web of Science ®Google Scholar
• Wake N, Hisashige A, Katayama T, et al. Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study. Diabetes Res Clin Pract. 2000;48(3):201–210.
   PubMed Web of Science ®Google Scholar
• Margolis KL, O’Connor PJ, Morgan TM, et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care. 2014;37(6):1721–1728.
   PubMed Web of Science ®Google Scholar
• Ohkuma T, Chalmers J, Cooper M, et al. The comparative effects of intensive glucose lowering in diabetes patients aged below or above 65 years: results from the ADVANCE trial. Diabetes Obes Metab. 2021;23(6):1292–1300.
   PubMed Web of Science ®Google Scholar
• Tian J, Ohkuma T, Cooper M, et al. Effects of intensive glycemic control on clinical outcomes among patients with type 2 Diabetes With different levels of cardiovascular risk and hemoglobin A(1c) in the ADVANCE Trial. Diabetes Care. 2020;43(6):1293–1299.
   PubMed Web of Science ®Google Scholar
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type. 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–853.
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589.
   PubMed Web of Science ®Google Scholar
• Clarke P, Gray A, Adler A, et al. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51). Diabetologia 2001;44(3):298–304.
   PubMed Web of Science ®Google Scholar
• Clarke PM, Gray AM, Briggs A, et al. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia. 2005;48(5):868–877.
   PubMed Web of Science ®Google Scholar
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type. 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352(9131):854–865.
   PubMed Web of Science ®Google Scholar
• Quality of life in type. 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). U.K. Prospective Diabetes Study Group. Diabetes Care. 1999;22(7):1125–1136.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes. Study (UKPDS). VIII. Study design, progress and performance. Diabetologia 1991;34(12):877–890.
   PubMed Web of Science ®Google Scholar
• Levin SR, Coburn JW, Abraira C, et al. Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators. Diabetes Care. 2000;23(10):1478–1485.
   PubMedGoogle Scholar
• Emanuele N, Klein R, Abraira C, et al. Evaluations of retinopathy in the VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM). A feasibility study. Diabetes Care. 1996;19(12):1375–1381.
   PubMed Web of Science ®Google Scholar
• Abraira C, Emanuele N, Colwell J, et al. Glycemic control and complications in type II diabetes. Design of a feasibility trial. VA CS Group (CSDM). Diabetes Care. 1992;15(11):1560–1571.
   PubMed Web of Science ®Google Scholar
• Pitale S, Kernan-Schroeder D, Emanuele N, et al. Health-related quality of life in the VA Feasibility Study on glycemic control and complications in type 2 diabetes mellitus. J Diabetes Complications. 2005;19(4):207–211.
   PubMed Web of Science ®Google Scholar
• Abraira C, Henderson WG, Colwell JA, et al. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM). Diabetes Care. 1998;21(4):574–579.
   PubMed Web of Science ®Google Scholar
• Abraira C, Colwell JA, Nuttall FQ, et al. Veterans affairs cooperative study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. veterans affairs cooperative study in type II Diabetes. Diabetes Care. 1995;18(8):1113–1123.
   PubMed Web of Science ®Google Scholar
• Abraira C, Duckworth W, McCarren M, et al. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: veterans Affairs Diabetes Trial. J Diabetes Complications. 2003;17(6):314–322.
   PubMed Web of Science ®Google Scholar
• Abraira C, Duckworth WC, Moritz T. Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report. Diabetes Obes Metab. 2009;11(2):150–156.
   PubMed Web of Science ®Google Scholar
• Slinin Y, Ishani A, Rector T, et al. Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and CKD: a systematic review for a KDOQI clinical practice guideline. Am J Kidney Dis. 2012;60(5):747–769.
   PubMed Web of Science ®Google Scholar
• Hemmingsen B, Lund SS, Gluud C, et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2013;(11):Cd008143
   PubMed Web of Science ®Google Scholar
• Stettler C, Allemann S, Jüni P, et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J. 2006;152(1):27–38.
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Koehler C, Hoffmann C, et al. Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early Type 2 diabetes. Diabet Med. 2010;27(2):175–180.
   PubMed Web of Science ®Google Scholar
• Coca SG, Ismail-Beigi F, Haq N, et al. Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med. 2012;172(10):761–769.
   PubMedGoogle Scholar